Increased glutamine

fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM

Hannele Yki-Järvinen, Marc C. Daniels, Antti Virkamäki, Sari Mäkimattila, Ralph A Defronzo, Don McClain

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Overactivity of the hexosamine pathway mediates glucose-induced insulin resistance in rat adipocytes. Glutamine:fructose-6-phosphate amidotransferase (GFA) is the rate-limiting enzyme of this pathway. We determined GFA activity in human skeletal muscle biopsies and rates of insulin-stimulated whole- body, oxidative, and nonoxidative glucose disposal using the euglycemic insulin clamp technique combined with indirect calorimetry (insulin infusion rate 1.5 mU · kg-1 · min-1) in 12 male patients with NIDDM (age 54 ±± 2 years, BMI 27.5 ± 0.9 kg/m2, fasting plasma glucose 8.5 ± 0.6 mmol/l) and 9 matched normal men. GFA activity was detectable in human skeletal muscles and completely inhibited by uridine-5'-diphospho-N-acetylglucosamine (UDP-GlcNAc) in all subjects. GFA activity was 46% increased in the NIDDM patients compared with the normal subjects (9.5 ± 1.3 vs. 6.5 ± 1.2 pmol, P < 0.05). Whole-body glucose uptake was 58% decreased in patients with NIDDM (20 ± 3 μmol · kg body wt-1 · min-1) compared with normal subjects (47 ± 4 μmol · kg body wt-1 · min-1, P < 0.001). This decrease was attributable to decreases in both glucose oxidation (9 ± 1 vs. 15 ± 1 μmol · kg-1 · min-1, NIDDM patients vs. control subjects, P < 0.002) and nonoxidative glucose disposal (11 ± 2 vs. 31 ± 4 μmol · kg-1 · min- 1, P < 0.001). In patients with NIDDM, both HbA(1c) (r = -0.51, P < 0.05) and BMI (r = -0.57, P < 0.05) correlated with whole-body glucose uptake. HbA(1c) but not BMI or insulin sensitivity was correlated with basal GFA activity (r = 0.57, P < 0.01) in NIDDM patients and control subjects. We conclude that GFA is found in human skeletal muscle and that all this activity is sensitive to feedback inhibition by UDP-GlcNAc. Chronic hyperglycemia is associated with an increase in skeletal muscle GFA activity, suggesting that increased activity of the hexosamine pathway may contribute to glucose toxicity and insulin resistance in humans.

Original languageEnglish (US)
Pages (from-to)302-307
Number of pages6
JournalDiabetes
Volume45
Issue number3
StatePublished - 1996

Fingerprint

Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing)
Type 2 Diabetes Mellitus
Skeletal Muscle
Glucose
Hexosamines
Insulin Resistance
Uridine Diphosphate
Insulin
Uridine Diphosphate N-Acetylglucosamine
Indirect Calorimetry
Glucose Clamp Technique
Adipocytes
Human Activities
Hyperglycemia
Fasting
Biopsy

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Yki-Järvinen, H., Daniels, M. C., Virkamäki, A., Mäkimattila, S., Defronzo, R. A., & McClain, D. (1996). Increased glutamine: fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM. Diabetes, 45(3), 302-307.

Increased glutamine : fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM. / Yki-Järvinen, Hannele; Daniels, Marc C.; Virkamäki, Antti; Mäkimattila, Sari; Defronzo, Ralph A; McClain, Don.

In: Diabetes, Vol. 45, No. 3, 1996, p. 302-307.

Research output: Contribution to journalArticle

Yki-Järvinen, H, Daniels, MC, Virkamäki, A, Mäkimattila, S, Defronzo, RA & McClain, D 1996, 'Increased glutamine: fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM', Diabetes, vol. 45, no. 3, pp. 302-307.
Yki-Järvinen H, Daniels MC, Virkamäki A, Mäkimattila S, Defronzo RA, McClain D. Increased glutamine: fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM. Diabetes. 1996;45(3):302-307.
Yki-Järvinen, Hannele ; Daniels, Marc C. ; Virkamäki, Antti ; Mäkimattila, Sari ; Defronzo, Ralph A ; McClain, Don. / Increased glutamine : fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM. In: Diabetes. 1996 ; Vol. 45, No. 3. pp. 302-307.
@article{ea22991539854830bef57f5dc53c8b5c,
title = "Increased glutamine: fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM",
abstract = "Overactivity of the hexosamine pathway mediates glucose-induced insulin resistance in rat adipocytes. Glutamine:fructose-6-phosphate amidotransferase (GFA) is the rate-limiting enzyme of this pathway. We determined GFA activity in human skeletal muscle biopsies and rates of insulin-stimulated whole- body, oxidative, and nonoxidative glucose disposal using the euglycemic insulin clamp technique combined with indirect calorimetry (insulin infusion rate 1.5 mU · kg-1 · min-1) in 12 male patients with NIDDM (age 54 ±± 2 years, BMI 27.5 ± 0.9 kg/m2, fasting plasma glucose 8.5 ± 0.6 mmol/l) and 9 matched normal men. GFA activity was detectable in human skeletal muscles and completely inhibited by uridine-5'-diphospho-N-acetylglucosamine (UDP-GlcNAc) in all subjects. GFA activity was 46{\%} increased in the NIDDM patients compared with the normal subjects (9.5 ± 1.3 vs. 6.5 ± 1.2 pmol, P < 0.05). Whole-body glucose uptake was 58{\%} decreased in patients with NIDDM (20 ± 3 μmol · kg body wt-1 · min-1) compared with normal subjects (47 ± 4 μmol · kg body wt-1 · min-1, P < 0.001). This decrease was attributable to decreases in both glucose oxidation (9 ± 1 vs. 15 ± 1 μmol · kg-1 · min-1, NIDDM patients vs. control subjects, P < 0.002) and nonoxidative glucose disposal (11 ± 2 vs. 31 ± 4 μmol · kg-1 · min- 1, P < 0.001). In patients with NIDDM, both HbA(1c) (r = -0.51, P < 0.05) and BMI (r = -0.57, P < 0.05) correlated with whole-body glucose uptake. HbA(1c) but not BMI or insulin sensitivity was correlated with basal GFA activity (r = 0.57, P < 0.01) in NIDDM patients and control subjects. We conclude that GFA is found in human skeletal muscle and that all this activity is sensitive to feedback inhibition by UDP-GlcNAc. Chronic hyperglycemia is associated with an increase in skeletal muscle GFA activity, suggesting that increased activity of the hexosamine pathway may contribute to glucose toxicity and insulin resistance in humans.",
author = "Hannele Yki-J{\"a}rvinen and Daniels, {Marc C.} and Antti Virkam{\"a}ki and Sari M{\"a}kimattila and Defronzo, {Ralph A} and Don McClain",
year = "1996",
language = "English (US)",
volume = "45",
pages = "302--307",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "3",

}

TY - JOUR

T1 - Increased glutamine

T2 - fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM

AU - Yki-Järvinen, Hannele

AU - Daniels, Marc C.

AU - Virkamäki, Antti

AU - Mäkimattila, Sari

AU - Defronzo, Ralph A

AU - McClain, Don

PY - 1996

Y1 - 1996

N2 - Overactivity of the hexosamine pathway mediates glucose-induced insulin resistance in rat adipocytes. Glutamine:fructose-6-phosphate amidotransferase (GFA) is the rate-limiting enzyme of this pathway. We determined GFA activity in human skeletal muscle biopsies and rates of insulin-stimulated whole- body, oxidative, and nonoxidative glucose disposal using the euglycemic insulin clamp technique combined with indirect calorimetry (insulin infusion rate 1.5 mU · kg-1 · min-1) in 12 male patients with NIDDM (age 54 ±± 2 years, BMI 27.5 ± 0.9 kg/m2, fasting plasma glucose 8.5 ± 0.6 mmol/l) and 9 matched normal men. GFA activity was detectable in human skeletal muscles and completely inhibited by uridine-5'-diphospho-N-acetylglucosamine (UDP-GlcNAc) in all subjects. GFA activity was 46% increased in the NIDDM patients compared with the normal subjects (9.5 ± 1.3 vs. 6.5 ± 1.2 pmol, P < 0.05). Whole-body glucose uptake was 58% decreased in patients with NIDDM (20 ± 3 μmol · kg body wt-1 · min-1) compared with normal subjects (47 ± 4 μmol · kg body wt-1 · min-1, P < 0.001). This decrease was attributable to decreases in both glucose oxidation (9 ± 1 vs. 15 ± 1 μmol · kg-1 · min-1, NIDDM patients vs. control subjects, P < 0.002) and nonoxidative glucose disposal (11 ± 2 vs. 31 ± 4 μmol · kg-1 · min- 1, P < 0.001). In patients with NIDDM, both HbA(1c) (r = -0.51, P < 0.05) and BMI (r = -0.57, P < 0.05) correlated with whole-body glucose uptake. HbA(1c) but not BMI or insulin sensitivity was correlated with basal GFA activity (r = 0.57, P < 0.01) in NIDDM patients and control subjects. We conclude that GFA is found in human skeletal muscle and that all this activity is sensitive to feedback inhibition by UDP-GlcNAc. Chronic hyperglycemia is associated with an increase in skeletal muscle GFA activity, suggesting that increased activity of the hexosamine pathway may contribute to glucose toxicity and insulin resistance in humans.

AB - Overactivity of the hexosamine pathway mediates glucose-induced insulin resistance in rat adipocytes. Glutamine:fructose-6-phosphate amidotransferase (GFA) is the rate-limiting enzyme of this pathway. We determined GFA activity in human skeletal muscle biopsies and rates of insulin-stimulated whole- body, oxidative, and nonoxidative glucose disposal using the euglycemic insulin clamp technique combined with indirect calorimetry (insulin infusion rate 1.5 mU · kg-1 · min-1) in 12 male patients with NIDDM (age 54 ±± 2 years, BMI 27.5 ± 0.9 kg/m2, fasting plasma glucose 8.5 ± 0.6 mmol/l) and 9 matched normal men. GFA activity was detectable in human skeletal muscles and completely inhibited by uridine-5'-diphospho-N-acetylglucosamine (UDP-GlcNAc) in all subjects. GFA activity was 46% increased in the NIDDM patients compared with the normal subjects (9.5 ± 1.3 vs. 6.5 ± 1.2 pmol, P < 0.05). Whole-body glucose uptake was 58% decreased in patients with NIDDM (20 ± 3 μmol · kg body wt-1 · min-1) compared with normal subjects (47 ± 4 μmol · kg body wt-1 · min-1, P < 0.001). This decrease was attributable to decreases in both glucose oxidation (9 ± 1 vs. 15 ± 1 μmol · kg-1 · min-1, NIDDM patients vs. control subjects, P < 0.002) and nonoxidative glucose disposal (11 ± 2 vs. 31 ± 4 μmol · kg-1 · min- 1, P < 0.001). In patients with NIDDM, both HbA(1c) (r = -0.51, P < 0.05) and BMI (r = -0.57, P < 0.05) correlated with whole-body glucose uptake. HbA(1c) but not BMI or insulin sensitivity was correlated with basal GFA activity (r = 0.57, P < 0.01) in NIDDM patients and control subjects. We conclude that GFA is found in human skeletal muscle and that all this activity is sensitive to feedback inhibition by UDP-GlcNAc. Chronic hyperglycemia is associated with an increase in skeletal muscle GFA activity, suggesting that increased activity of the hexosamine pathway may contribute to glucose toxicity and insulin resistance in humans.

UR - http://www.scopus.com/inward/record.url?scp=0030042488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030042488&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 302

EP - 307

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 3

ER -